A photodynamic probe targeting high-risk HPV-infected cervical cells and its preparation method and application
By designing photosensitizers and fluorescent probes targeting HR-HPV cells, using near-infrared light to excite ROS, combined with galactose lectin 1 inhibitor, the problem of poor photodynamic treatment is solved, and the HR-HPV treatment is achieved Efficient targeted therapy and immune activation of cells.
Patent Information
- Application Number
- CN202410244995.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-03-05
AI Technical Summary
In existing photodynamic treatments, the photosensitizer has a long half-life, high skin accumulation, poor water solubility, and low bioavailability, resulting in poor treatment effects and it is difficult to target cervical cells infected with high-risk HPV.
Design a photosensitive agent targeting HR-HPV cells, generate high-efficiency ROS under near-infrared light excitation through specific compound structures, and combine with galactose lectin 1 inhibitor to prepare a TBTCN-TDG fluorescent probe to improve HR - Targeting and immune activation ability of HPV cells.
It has achieved efficient targeted treatment of HR-HPV cells, reduced viral load, activated immune response, and had high ROS generation efficiency, low cytotoxicity and low skin phototoxicity.
Smart Images

Figure BDA0004725579070000021 
Figure BDA0004725579070000031 
Figure BDA0004725579070000041
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to a photodynamic probe targeting high-risk HPV-infected cervical cells and a preparation method and application thereof. Background Art
[0002] Human papillomavirus (HPV) is a type of virus that is widely present in nature. It has a very high infection rate and is associated with the occurrence and development of various cervical lesions. People infected with high-risk human papillomavirus (HR-HPV) are persistently infected and can develop cervical intraepithelial neoplasia (CIN) and cervical cancer. The common clinical treatments for cervical HR-HPV infection are mainly drug therapy, surgical treatment, physical therapy and comprehensive treatment, but there is still a lack of recognized and effective treatment methods. Therefore, exploring an effective method to treat persistent cervical HR-HPV infection is of great clinical significance for preventing CIN and cervical cancer.
[0003] Photodynamic therapy (PDT) is a new non-invasive treatment method with the characteristics of low trauma, high selectivity and low toxicity. PDT excites photosensitizers through specific light sources, produces ROS in the diseased tissue, directly kills diseased cells, destroys blood vessels and stimulates the body's immune response to produce a powerful therapeutic effect. Some studies have attempted to apply the second-generation photosensitizer, 5-ALA, to the surface of the cervix, using photodynamic therapy to treat cervical intraepithelial neoplasia and remove HPV. The first and second generation photosensitizers currently used in clinical practice generally have problems such as long half-life, high accumulation in the skin, poor water solubility, low bioavailability, low photobleaching and photothermal efficiency, poor stability and lack of tumor cell targeting specificity. The drug concentration difference between the diseased tissue and the normal cervical tissue is small, the drug is difficult to penetrate the entire layer of the lesion, the laser penetration distance is short, and there are limitations on deeper and larger lesions, resulting in poor treatment effects. Therefore, it is urgent to develop a new fluorescent probe targeting HPV to achieve targeted photodynamic therapy for persistent HPV infection. Summary of the invention
[0004] The present invention aims to solve one of the above problems by designing a fluorescent probe targeting HR-HPV cells, improving the aggregation ability of photosensitizers in diseased cells, generating high-efficiency ROS-induced autophagy under near-infrared light excitation, activating innate and adaptive immunity, and reducing the viral load of high-risk HPV, so as to achieve targeted photodynamic therapy for persistent HR-HPV infection.
[0005] The first aspect of the present invention aims to provide a photosensitizer.
[0006] The purpose of the second aspect of the present invention is to provide a method for preparing the photosensitizer of the first aspect of the present invention.
[0007] The purpose of the third aspect of the present invention is to provide the use of the photosensitizer of the first aspect of the present invention in the preparation of a photodynamic probe.
[0008] The fourth aspect of the present invention aims to provide a photodynamic probe.
[0009] The purpose of the fifth aspect of the present invention is to provide a method for preparing the photodynamic probe of the fourth aspect of the present invention.
[0010] The purpose of the sixth aspect of the present invention is to provide an application of the photosensitizer of the first aspect of the present invention or the photodynamic probe of the fourth aspect of the present invention.
[0011] The seventh aspect of the present invention is to provide a product
[0012] In order to achieve the above object, the technical solution adopted by the present invention is:
[0013] The first aspect of the present invention provides a photosensitizer, wherein the photosensitizer is a compound represented by formula (I):
[0014]
[0015] Formula (I).
[0016] The second aspect of the present invention provides a method for preparing the photosensitizer of the first aspect of the present invention, comprising the following steps:
[0017] (1) Using 4-boric acid triphenylamine, 5-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carboxaldehyde, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride as raw materials, K2CO3 solution, ethanol and toluene as solvents, react under N2 protection to obtain an intermediate;
[0018] (2) The intermediate obtained in step (1) is mixed with 2-cyanoacetic acid, acetic acid and ammonium acetate, and reacted under N2 protection to obtain the photosensitizer.
[0019] In some embodiments of the present invention, the reaction conditions in step (1) are 80-90° C. for 10-14 hours.
[0020] In some preferred embodiments of the present invention, the reaction conditions in step (1) are 80-85° C. for 10-12 hours.
[0021] In some more preferred embodiments of the present invention, the reaction conditions in step (1) are 85° C. for 12 h.
[0022] In some embodiments of the present invention, the reaction in step (1) is a heating reflux reaction.
[0023] In some embodiments of the present invention, the reaction conditions in step (2) are 100-120° C. for 10-14 h.
[0024] In some preferred embodiments of the present invention, the reaction conditions in step (2) are 110-120° C. for 10-12 h.
[0025] In some more preferred embodiments of the present invention, the reaction conditions in step (2) are 110° C. for 12 h.
[0026] In some embodiments of the present invention, the reaction in step (2) is a heating reflux reaction.
[0027] In some embodiments of the present invention, the intermediate is 5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carbaldehyde, and its structural formula is as follows:
[0028]
[0029] In some embodiments of the present invention, the mass ratio of 4-boric acid triphenylamine, 5-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carboxaldehyde, and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride is 1:0.3-0.8:0.1-0.5.
[0030] In some preferred embodiments of the present invention, the mass ratio of 4-boric acid triphenylamine, 5-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carboxaldehyde, and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride is 1:0.4-0.6:0.1-0.3.
[0031] In some more preferred embodiments of the present invention, the mass ratio of 4-boric acid triphenylamine, 5-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carbaldehyde, and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium is 1:0.5-0.6:0.2-0.3.
[0032] In some embodiments of the present invention, the mass volume ratio (g / mL) of the 4-boric acid triphenylamine to ethanol and toluene is 1:5-10:5-12.
[0033] In some preferred embodiments of the present invention, the mass volume ratio (g / mL) of the 4-boric acid triphenylamine to ethanol and toluene is 1:5-8:7-12.
[0034] In some embodiments of the present invention, the mass volume ratio (g / mL) of the 4-boric acid triphenylamine to ethanol and toluene is 1:6-7:10-12.
[0035] In some embodiments of the present invention, the mass ratio of the intermediate, 2-cyanoacetic acid and ammonium acetate is 1:1-4:0.1-0.5.
[0036] In some preferred embodiments of the present invention, the mass ratio of the intermediate, 2-cyanoacetic acid and ammonium acetate is 1:1-2:0.1-0.3.
[0037] In some more preferred embodiments of the present invention, the mass ratio of the intermediate, 2-cyanoacetic acid and ammonium acetate is 1:1-2:0.1-0.2.
[0038] In some embodiments of the present invention, the mass volume ratio (mg / mL) of ammonium acetate to acetic acid is 4 to 6:1.
[0039] The third aspect of the present invention provides use of the photosensitizer according to the first aspect of the present invention in the preparation of a photodynamic probe.
[0040] The fourth aspect of the present invention provides a photodynamic probe, comprising the photosensitizer of the first aspect of the present invention.
[0041] In some embodiments of the present invention, the photodynamic probe further comprises a galectin-1 inhibitor.
[0042] In some embodiments of the present invention, the galectin-1 inhibitor comprises D-galactopyranose B-thiogalactopyranoside.
[0043] In some embodiments of the present invention, the photodynamic probe is a compound represented by formula (II):
[0044]
[0045] Formula (II).
[0046] In some embodiments of the present invention, the particle size of the photodynamic probe is 50 nm to 60 nm.
[0047] In some embodiments of the present invention, the ultraviolet absorption peak of the photodynamic probe is 490nm to 500nm.
[0048] In some embodiments of the present invention, the fluorescence absorption peak of the photodynamic probe is 630nm-640nm.
[0049] The fifth aspect of the present invention provides a method for preparing the photodynamic probe of the fourth aspect of the present invention, comprising the following steps: mixing a photosensitizer and D-galactopyranose BD-thiogalactopyranoside with dichloromethane and a coupling agent, and reacting them to obtain a photodynamic probe.
[0050] In some embodiments of the present invention, the coupling agent includes EDC and NHS.
[0051] In some embodiments of the present invention, the mass ratio of EDC to NHS is 1 to 3:1.
[0052] In some preferred embodiments of the present invention, the mass ratio of EDC to NHS is 1-2:1.
[0053] In some embodiments of the present invention, the reaction is carried out at room temperature for 10 to 14 hours.
[0054] In some preferred embodiments of the present invention, the reaction is carried out at room temperature for 12 to 14 hours.
[0055] In some more preferred embodiments of the present invention, the reaction is carried out at room temperature for 12 hours.
[0056] In some embodiments of the present invention, the mass ratio of the photosensitizer to D-galactopyranose BD-thiogalactopyranoside and the coupling agent is 1-3:1:0.5-1.5.
[0057] In some preferred embodiments of the present invention, the mass ratio of the photosensitizer to D-galactopyranose BD-thiogalactopyranoside and the coupling agent is 2:1:0.918.
[0058] In some embodiments of the present invention, the mass volume ratio (mg / mL) of D-galactopyranose BD-thiogalactopyranoside to dichloromethane is 1:1-2.
[0059] In some embodiments of the present invention, the preparation method further comprises the steps of washing with water, separating the organic phase, and evaporating the organic phase.
[0060] The sixth aspect of the present invention provides the use of the photosensitizer of the first aspect of the present invention or the photodynamic probe of the fourth aspect of the present invention in at least one of (a1) to (a6):
[0061] (a1) preparing a photodynamic diagnostic and therapeutic agent;
[0062] (a2) Bioimaging for non-disease diagnosis and treatment;
[0063] (a3) preparing drugs for treating diseases related to human papillomavirus infection;
[0064] (a4) preparing tumor imaging drugs;
[0065] (a5) producing ROS;
[0066] (a6) Reduce HPV viral load.
[0067] A seventh aspect of the present invention provides a product, wherein the product comprises the photodynamic probe according to the fourth aspect of the present invention.
[0068] In some embodiments of the present invention, the products include but are not limited to reagents, kits and drugs.
[0069] In some embodiments of the present invention, the product has at least one of the following functions:
[0070] (1) Biological imaging;
[0071] (2) Preparation of ROS;
[0072] (3) Reduce HPV viral load;
[0073] (4) Treatment of diseases related to human papillomavirus infection.
[0074] The beneficial effects of the present invention are:
[0075] The photosensitizer provided by the present invention has the advantages of higher ROS generation efficiency, faster self-degradation ability, low cytotoxicity, low skin phototoxicity, etc. Compared with the commonly used clinical photosensitizers such as 5-ALA, the photosensitizer is easy to modify and functionalize, providing options for designing other tumor-targeting probes.
[0076] Based on the current clinical problem of persistent HR-HPV infection without effective treatment, literature reports that galectin-1 (Gal-1) is highly expressed in HPV16-integrated SiHa cell lines, HPV18-integrated HeLa and CaSki cell lines, and lowly expressed in HPV-negative HT-3 and C-33A cell lines and normal cervical tissues. Therefore, Gal-1 can be used as a photosensitizer target to improve the targeting of the probe to HR-HPV. The present invention proposes to use Gal-1 and its small molecule inhibitor TDG as targets and targets, thereby designing a photodynamic probe targeting HR-HPV cells (i.e., TBTCN-TDG fluorescent probe). The probe has the ability to target high-risk HPV-infected cells, and has the advantages of higher ROS generation efficiency, accelerated self-degradation ability, low cytotoxicity, and low skin phototoxicity. Under near-infrared light excitation, high-efficiency ROS is generated to induce autophagy, activate natural and adaptive immunity, reduce high-risk HPV viral load, and eliminate HPV by enhancing the body's immunity, so as to achieve targeted photodynamic therapy for persistent HR-HPV infection. This photodynamic probe has strong practical application value in analytical chemistry, life sciences and other fields.
[0077] The photodynamic probe provided by the present invention can be obtained by chemical synthesis, and the synthesis process is simple and easy, the raw materials are cheap and easily available, the preparation cost is low, and it is easy to promote. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1 A reaction formula of a TBTCN-TDG fluorescent probe is provided for an embodiment of the present invention.
[0079] Figure 2 The particle size of the TBTCN-TDG fluorescent probe provided in the embodiment of the present invention.
[0080] Figure 3 This is the ultraviolet absorption spectrum of the TBTCN-TDG fluorescent probe provided in the embodiment of the present invention.
[0081] Figure 4 This is the fluorescence absorption spectrum of the TBTCN-TDG fluorescent probe provided in the embodiment of the present invention.
[0082] Figure 5 Fourier infrared spectra of the TBTCN-TDG fluorescent probe and TBTCN fluorescent probe provided in the embodiments of the present invention.
[0083] Figure 6 This is the hydrogen nuclear magnetic resonance spectrum of the TBTCN-TDG fluorescent probe provided in an embodiment of the present invention.
[0084] Figure 7 The fluorescence intensity of the TBTCN-TDG fluorescent probe and the TBTCN fluorescent probe provided in the embodiments of the present invention is measured in Siha (HPV+) cells at different uptake times.
[0085] Figure 8 Intracellular reactive oxygen species (ROS) detection of the TBTCN-TDG fluorescent probe and the TBTCN fluorescent probe provided in the embodiments of the present invention in Siha (HPV+) cells after 1 hour of uptake and illumination, with a scale of 50 μm.
[0086] Fig. 9 The TBTCN-TDG fluorescent probe provided in the embodiment of the present invention is injected into the tumor and then subjected to light treatment to show the change in tumor volume.
[0087] Fig.10 This is an analysis of the toxicity of the TBTCN-TDG fluorescent probe and the TBTCN fluorescent probe provided in the embodiments of the present invention to important organs in vivo. DETAILED DESCRIPTION
[0088] The present invention is further described in detail below through specific examples.
[0089] It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0090] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0091] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0092] Example 1
[0093] A TBTCN-TDG fluorescent probe is prepared by coupling D-galactopyranose BD-thiodigalactoside (TDG) with a small molecule fluorescent probe TBTCN.
[0094] The preparation method of the above-mentioned TBTCN-TDG fluorescent probe ( Figure 1 ), including the following steps:
[0095] (1) Synthesis of 5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carboxaldehyde
[0096] In a 100 mL flask, add 2.89 g of 4-boronic acid triphenylamine (10 mmol), 1.625 g of 5-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carbaldehyde (10 mmol), 0.731 g of [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (PdC12(dppf)) (1 mmol), 5 mL of 2M K2CO3 solution, 20 mL of ethanol, and 30 mL of toluene. Drain N2 for 30 min, and heat under reflux at 85°C under N2 protection for 12 h. After the reaction, the reaction solution was washed with water, the organic phase was separated, the organic solvent was evaporated, and n-hexane and ethyl acetate (V:V=9:1) were used as eluents for purification by silica gel column chromatography to obtain the product 5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carbaldehyde.
[0097] (2) Synthesis of (E)-2-cyano-3-(5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophen-2-yl)acrylic acid (TBTCN fluorescent probe)
[0098] In a 50mL flask, add 0.489g 5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-carboxaldehyde (1mmol), 0.87g 2-cyanoacetic acid (1.2mmol), 10mL acetic acid, 50mg ammonium acetate, and blow N2 for 30min. Heat under reflux at 110℃ for 12h under N2 protection. After the reaction, wash the reaction solution with water and filter to obtain the product (E)-2-cyano-3-(5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-yl)acrylic acid, which is named TBTCN fluorescent probe.
[0099] (3) Synthesis of (3,4,5-trihydroxy-6-((hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)tetrahydro-1H-pyran-2-yl)methyl (E)-2-cyano-3-(5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophen-2-yl)acrylate (TBTCN-TDG probe)
[0100] In a 50 mL flask, add 20 mg of (E)-2-cyano-3-(5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophen-2-yl)acrylic acid (0.035 mmol), 10 mg of D-galactopyranosyl B-thiogalactopyranosyl (0.028 mmol), 10 mL of dichloromethane, 5.73 mg of EDC, and 3.45 mg of NHS, and react at room temperature for 12 h. After the reaction, the reaction solution was washed with water, the organic phase was separated, and the organic solvent was evaporated to obtain the product (3,4,5-trihydroxy-6-((hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)tetrahydro-1H-pyran-2-yl)methyl (E)-2-cyano-3-(5-(7-(4-(diphenylamino)phenyl)benzo[c][1,2,5]thiadiazol-4-yl)thiophene-2-yl)acrylate, which was named TBTCN-TDG fluorescent probe.
[0101] Example 2 Characterization and measurement of TBTCN-TDG fluorescent probe
[0102] In this example, the TBTCN-TDG fluorescent probe prepared in Example 1 is characterized as follows:
[0103] 1. Particle size of TBTCN-TDG fluorescent probe
[0104] The particle size and particle size distribution of TBTCN-TDG fluorescent probe aqueous solution were determined by dynamic light scattering (Malvern Zetasizer Nano-ZS, UK).
[0105] The results of the test are as follows Figure 2 As shown, the particle size of the TBTCN-TDG fluorescent probe of Example 1 is 50 nm to 60 nm.
[0106] 2. Ultraviolet characteristic absorption peak of TBTCN-TDG fluorescent probe
[0107] The spectrum of the TBTCN-TDG fluorescent probe aqueous solution was scanned in the wavelength range of 300-800 nm using a fluorescence spectrophotometer (ND-10001, NanoDrop, USA) to analyze the ultraviolet characteristic absorption peak.
[0108] The results of the test are as follows Figure 3 As shown, the ultraviolet absorption peak of the TBTCN-TDG fluorescent probe of Example 1 is 490-500 nm.
[0109] 3. Fluorescence characteristic absorption peak of TBTCN-TDG fluorescent probe
[0110] The spectrum of the TBTCN-TDG fluorescent probe aqueous solution was scanned in the wavelength range of 500-900 nm using a fluorescence spectrophotometer (ND-10001, NanoDrop, USA) to analyze the ultraviolet characteristic absorption peak.
[0111] The results of the test are as follows Figure 4 As shown, the fluorescence absorption peak of the TBTCN-TDG fluorescent probe of Example 1 is 630-640 nm.
[0112] 4. Fourier transform infrared spectroscopy (FITR) analysis of TBTCN-TDG fluorescent probe
[0113] FTIR analyzer was used at 400-4000cm -1 The infrared spectrum of TBTCN-TDG fluorescent probe was obtained at a frequency of .
[0114] The results are as follows Figure 5 shown.
[0115] 5.1H NMR spectrum of TBTCN-TDG fluorescent probe dissolved in deuterated DMSO solution
[0116] The results are as follows Figure 6 shown.
[0117] Example 3 Verification of the targeting of TBTCN-TDG fluorescent probe to Siha (HPV+) cells
[0118] This example is used to verify the targeting of the TBTCN-TDG fluorescent probe of Example 1 to Siha (HPV+) cells, as follows:
[0119] TBTCN-TDG fluorescent probe and TBTCN fluorescent probe at a concentration of 10 μg / mL were co-incubated with Siha (HPV+) cells in a 37°C, 5% CO2 incubator. The cells were digested with trypsin after 0.5 h, 1 h, 2 h, 3 h, 4 h, and 5 h, and washed three times with PBS to remove the fluorescent probes not taken up by the cells. The cells were resuspended in PBS, and the intracellular probe fluorescence intensity was measured by flow cytometry.
[0120] The results are as follows Figure 7 As shown, compared with the TBTCN fluorescent probe, the TBTCN-TDG fluorescent probe is taken up faster and in a larger amount in Siha (HPV+) cells.
[0121] Example 4 Verification of the photodynamic effect of TBTCN-TDG fluorescent probe in cells
[0122] This example is used to verify the photodynamic effect of the TBTCN-TDG fluorescent probe in Example 1 in cells, as follows:
[0123] SiHa cells 1×10 5 Cells / well Cells were inoculated into six-well culture plates for 24 hours, and TBTCN-TDG fluorescent probes and TBTCN fluorescent probes at a concentration of 10 μg / mL were co-incubated with Siha (HPV+) cells for 1 hour and then irradiated with light (power 800 W, 5 min). After removing the complete culture medium, 300 μL DCFH-DA (10 mmol / L) was added, and the cells were incubated at 37 ° C in the dark for 20 minutes. Then, SiHa cells were washed three times with PBS buffer to completely remove DCFH-DA that did not enter the cells, and the level of intracellular reactive oxygen species (ROS) was measured under a fluorescence microscope.
[0124] The results are as follows Figure 8 As shown, TBTCN-TDG fluorescent probe produces ROS with high efficiency, and the photodynamic effect of TBTCN-TDG fluorescent probe in cells is better than that of TBTCN fluorescent probe.
[0125] Example 5 Analysis of the therapeutic effect of TBTCN-TDG fluorescent probe in vivo
[0126] This example is used to analyze the therapeutic effect of the TBTCN-TDG fluorescent probe of Example 1 in vivo, as follows:
[0127] SiHa (HPV+) cells were implanted subcutaneously in female Balb / c nude mice to establish a high-risk HPV infection model. Ten nude mice were randomly divided into two groups to receive the following treatments: PBS group (control group) and TBTCN-TDG+PDT group. After TBTCN-TDG fluorescent probe was injected into the lesion, the local lesion was irradiated with excitation light of a specific wavelength. After 7 consecutive days of treatment, the tumor volume was measured.
[0128] The results are as follows Fig. 9 As shown, after the tumor was treated with TBTCN-TDG+PDT, the tumor volume was significantly reduced compared with the control group.
[0129] Example 6 Toxicity analysis of TBTCN-TDG fluorescent probe
[0130] This example is used to analyze the toxicity of the TBTCN-TDG fluorescent probe of Example 1, as follows:
[0131] SiHa (HPV+) cells were subcutaneously implanted in female Balb / c nude mice to establish a high-risk HPV infection model. Fifteen nude mice were randomly divided into three groups to receive the following treatments: normal saline (NS) group, TBTCN group, and TBTCN-TDG+PDT group. After injection of TBTCN-TDG fluorescent probe or TBTCN fluorescent probe into the lesion, the local lesion was irradiated with excitation light of a specific wavelength. After 7 days of continuous treatment, the mice were killed, and the heart, liver, spleen, lung, kidney, and brain tissues were removed for histological examination. All organs were fixed in 10% formalin for 3 days, followed by tissue dehydration, paraffin embedding, and sectioning for HE staining. Whole slide scanning and analysis at 20 times magnification was performed using advanced optical microscopy equipment.
[0132] The results are as follows Fig.10 As shown, TBTCN-TDG fluorescent probe and TBTCN fluorescent probe have no toxicity to important organs in nude mice.
[0133] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A photodynamic probe, wherein the photodynamic probe is a compound represented by formula (II):
2. The method for preparing the photodynamic probe according to claim 1, comprising the following steps: The photosensitizer and D-galactopyranose BD-thiogalactopyranoside are mixed with dichloromethane and a coupling agent to react, thereby obtaining a photodynamic probe; The photosensitizer is a compound represented by formula (I):
3. Use of the photodynamic probe according to claim 1 in at least one of (a1) to (a6): (a1) preparing a photodynamic diagnostic and therapeutic agent; (a2) Bioimaging for non-disease diagnosis and treatment; (a3) preparing drugs for treating diseases related to human papillomavirus infection; (a4) preparing tumor imaging drugs; (a5) producing ROS; (a6) Reduce HPV viral load.
4. A product comprising the photodynamic probe according to claim 1.
